From: Harnessing cancer stem cell-derived exosomes to improve cancer therapy
CSCs | Non-CSCs |
---|---|
Small amount (0.01–2%), rare within tumors most of the time, but can increase to more than 30% in short time [15] | Large quantity, almost majority within tumors |
Self-renewal, multipotency, and symmetric/asymmetric divisions | Limited proliferation and symmetric divisions |
Reside predominantly in hypoxic, low pH and low nutrient niches [16] | Stochastic distribution |
Dysregulated cell cycle, reversible cellular quiescence capability [17] | None |
High tumorigenic capacity | low |
Ability to induce therapeutic resistance [18] | The main target of treatment until the emergence of unresponsive cancer cells |
Highly responsive to changes in the tumor microenvironment | low |
High heterogeneity than non-CSCs counterpart in tumors | Low heterogeneity |
Ability to arrange a hierarchy of daughter cells [19] | None |